Refining Current Treatment for Cats with Injection Site Sarcomas
Injection site sarcomas (also known as a fibrosarcoma) are a rare tumor that can arise following injections in cats. While a specific cause is yet to be determined, there are treatments available such as the anti-cancer drug carboplatin. Drs. Kelly Hume and Cheryl Balkman of the oncology department are performing a study to determine if customized doses based on kidney function (rather than body weight) will be effective against the tumor.
ELIGIBILITY: Cats must have a measurable tumor greater than 2 cm with confirmation of tumor type from histology (via incisional biopsy) at the time of study enrollment. Tumor may be primary tumor or metastatic lesion.
COMPENSATION: The study pays for cost of a physical exam, blood work, specialized kidney function testing (called iohexol clearance), two carboplatin treatments, and blood work monitoring after treatment. This reflects a cost savings of $900. Owners pay for initial staging costs that may be required such as x-rays and ultrasound.
OWNER RESPONSIBILITIES: Initial visits can last anywhere from 6-8 hours but the owner is not required to remain in the hospital. A minimum of 2 additional follow-up visits are required, approximately 3–4 weeks apart. Weekly blood work monitoring in between these visits is required, but can be performed elsewhere. Owners will be responsible for the cost of monitoring/blood work not performed at Cornell.